Gri Bio Etf Performance
| GRI Etf | USD 2.56 0.30 10.49% |
The etf retains a Market Volatility (i.e., Beta) of -1.88, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning GRI Bio are expected to decrease by larger amounts. On the other hand, during market turmoil, GRI Bio is expected to outperform it.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days GRI Bio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Etf's basic indicators remain fairly strong which may send shares a bit higher in March 2026. The recent confusion may also be a sign of long-lasting up-swing for the Etf traders. ...more
Last Split Factor 1:28 | Last Split Date 2026-01-26 |
1 | GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis | 12/10/2025 |
2 | GRI Bio Announces Pricing of 8,000,000 Million Public Offering | 12/11/2025 |
3 | GRI Bio Announces Closing of 8.0 Million Public Offering | 12/12/2025 |
4 | Acquisition by Hertz Walter Marc of 129730 shares of GRI Bio at 0.6857 subject to Rule 16b-3 | 01/06/2026 |
5 | GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621 | 01/08/2026 |
6 | GRI Bio To Carry Out 1-for-28 Reverse Stock Split On January 26th, 2026 - | 01/23/2026 |
7 | Wall Street Zen Downgrades GRI Bio to Strong Sell | 02/02/2026 |
GRI Bio Relative Risk vs. Return Landscape
If you would invest 4,704 in GRI Bio on November 5, 2025 and sell it today you would lose (4,449) from holding GRI Bio or give up 94.58% of portfolio value over 90 days. GRI Bio is generating negative expected returns assuming volatility of 11.6214% on return distribution over 90 days investment horizon. In other words, majority of equities are less volatile than GRI, and most equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
IPO Date 10th of February 2021 | 200 Day MA 40.0694 | 50 Day MA 22.0696 | Beta (1.25) |
GRI Bio Target Price Odds to finish over Current Price
The tendency of GRI Etf price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.56 | 90 days | 2.56 | about 87.5 |
Based on a normal probability distribution, the odds of GRI Bio to move above the current price in 90 days from now is about 87.5 (This GRI Bio probability density function shows the probability of GRI Etf to fall within a particular range of prices over 90 days) .
GRI Bio Price Density |
| Price |
Predictive Modules for GRI Bio
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as GRI Bio. Regardless of method or technology, however, to accurately forecast the etf market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the etf market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.GRI Bio Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. GRI Bio is not an exception. The market had few large corrections towards the GRI Bio's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold GRI Bio, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of GRI Bio within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -3.48 | |
β | Beta against Dow Jones | -1.88 | |
σ | Overall volatility | 21.87 | |
Ir | Information ratio | -0.32 |
GRI Bio Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of GRI Bio for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for GRI Bio can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| GRI Bio generated a negative expected return over the last 90 days | |
| GRI Bio has high historical volatility and very poor performance | |
| GRI Bio has high likelihood to experience some financial distress in the next 2 years | |
| GRI Biohas 700,747 shares shorted by GRI Bio investors is about 100% of outstending shares | |
| Reported Net Loss for the year was (11.96 M) with profit before taxes, overhead, and interest of 0. | |
| GRI Bio has about 183.82 M in cash with (10.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.3. | |
| Latest headline from thelincolnianonline.com: Wall Street Zen Downgrades GRI Bio to Strong Sell | |
| The fund retains 99.63% of its assets under management (AUM) in equities |
GRI Bio Fundamentals Growth
GRI Etf prices reflect investors' perceptions of the future prospects and financial health of GRI Bio, and GRI Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GRI Etf performance.
| Return On Equity | -2.38 | ||||
| Return On Asset | -1.04 | ||||
| Current Valuation | (2.19 M) | ||||
| Shares Outstanding | 536.3 K | ||||
| Price To Earning | 23.35 X | ||||
| Price To Book | 0.29 X | ||||
| EBITDA | (11.97 M) | ||||
| Cash And Equivalents | 183.82 M | ||||
| Cash Per Share | 0.30 X | ||||
| Total Debt | 2.66 M | ||||
| Debt To Equity | 1.23 % | ||||
| Book Value Per Share | 12.07 X | ||||
| Cash Flow From Operations | (10.19 M) | ||||
| Earnings Per Share | (121.80) X | ||||
| Total Asset | 8.67 M | ||||
| Retained Earnings | (51.7 M) | ||||
| Current Asset | 1.22 B | ||||
| Current Liabilities | 243.82 M | ||||
About GRI Bio Performance
By evaluating GRI Bio's fundamental ratios, stakeholders can gain valuable insights into GRI Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if GRI Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if GRI Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
The investment seeks investment results that correspond generally to the performance, before the funds fees and expenses, of an index called the Cohen Steers Global Realty Majors Index. Cohen Steers is traded on Archipelago Exchange in USA.| GRI Bio generated a negative expected return over the last 90 days | |
| GRI Bio has high historical volatility and very poor performance | |
| GRI Bio has high likelihood to experience some financial distress in the next 2 years | |
| GRI Biohas 700,747 shares shorted by GRI Bio investors is about 100% of outstending shares | |
| Reported Net Loss for the year was (11.96 M) with profit before taxes, overhead, and interest of 0. | |
| GRI Bio has about 183.82 M in cash with (10.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.3. | |
| Latest headline from thelincolnianonline.com: Wall Street Zen Downgrades GRI Bio to Strong Sell | |
| The fund retains 99.63% of its assets under management (AUM) in equities |
Other Information on Investing in GRI Etf
GRI Bio financial ratios help investors to determine whether GRI Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GRI with respect to the benefits of owning GRI Bio security.